paclitaxel has been researched along with Minimal Disease, Residual in 102 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (9.80) | 18.2507 |
| 2000's | 33 (32.35) | 29.6817 |
| 2010's | 51 (50.00) | 24.3611 |
| 2020's | 8 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Ballman, K; Bellon, JR; Campbell, JD; Carey, LA; Collyar, D; Fan, C; Fernandez-Martinez, A; Golshan, M; Hahn, OM; Hoadley, KA; Hu, Z; Hudis, CA; Hyslop, T; Kuzma, C; Li, Y; Ma, C; Mamounas, E; Parker, JS; Partridge, A; Perou, CM; Polley, MC; Port, ER; Selitsky, S; Shepherd, JH; Sikov, WM; Singh, B; Soloway, MG; Somlo, G; Spears, PA; Tolaney, SM; Winer, EP | 1 |
| He, J; He, Q; Li, J; Li, M; Long, Y; Qiu, Y; Ren, K; Wang, X; Xu, Z; Yang, Y; Zang, S; Zhang, Z | 1 |
| Blohmer, JU; Böhmer, G; Domröse, C; Favero, G; Hertel, H; Jacob, A; Jülicher, A; Köhler, C; Marnitz, S; Oppelt, P; Petzel, A; Plaikner, A; Ragosch, V; Schneider, A; Schubert, M; Siegler, K; Willems, A | 1 |
| Bizzarri, N; D'Indinosante, M; Fagotti, A; Garganese, G; Ghirardi, V; Loverro, M; Moruzzi, MC; Pasciuto, T; Scambia, G; Vargiu, V | 1 |
| Fan, Z; He, Y; Li, J; Li, Y; Ouyang, T; Wang, L; Wang, T; Xie, Y | 1 |
| Arjona-Sanchez, A; Aziz, O; Briceño, J; Casado-Adam, A; Esquivel, J; Glehen, O; Nedelcut, DS; Passot, G; Piso, P; Rodriguez-Ortiz, L; Rufian-Peña, S; Salti, G; Sanchez-Hidalgo, JM; Selvasekar, CR; Sommariva, A; Turaga, K; Van der Speeten, K; Yonemura, Y | 1 |
| Chen, C; Chen, KN; Dai, L; Du, M; Fang, Y; Gong, L; Hou, Y; Jiang, H; Jiao, J; Li, H; Li, K; Li, W; Li, Z; Lian, C; Liao, Y; Liu, J; Shen, Y; Tan, L; Tang, H; Wang, H; Wu, H; Xie, D; Yin, J; Zeng, Z; Zhao, Q; Zheng, B; Zhu, J | 1 |
| Ahmed, AA; Albukhari, A; Alsaadi, A; Artibani, M; Bast, RC; Blagden, SP; Campo, L; Chong, K; Damato, S; Dhar, S; Ejsing, CS; El-Sahhar, S; Gleeson, F; Harris, AL; Hu, Z; KaramiNejadRanjbar, M; Klemm, RW; Laios, A; Lu, Z; Mallett, G; Masuda, K; Morotti, M; Motohara, T; Nicum, S; Pathiraja, PN; Rauher, PC; Santana Gonzalez, L; Sauka-Spengler, T; Wietek, N; Yau, C; Zois, CE | 1 |
| Kang, S; Kim, SH; Lim, MC; Park, SY; Seo, SS; Song, YJ; Yoo, CW; Yoo, HJ | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Chen, PY; Huang, CY; Lin, FW; Wang, CK; Wei, KC; Yang, HW | 1 |
| Bristow, RE; Burger, RA; Eskander, RN; Fujiwara, K; Glaser, GE; Hamilton, CA; Huh, WK; Kauderer, J; Mannel, RS; O'Malley, DM; Rubin, SC; Stephan, JM; Tewari, KS; Ueland, F | 1 |
| Aigner, T; Göbel, H; Grabenbauer, GG; Leibl, B; Vitz, S | 1 |
| Beale, P; Bertrand, MA; Cervantes, A; Embleton, AC; González Martín, A; Kaplan, RS; Kent, E; Kristensen, G; Ledermann, JA; Oza, AM; Parmar, MKB; Perren, TJ; Pfisterer, J; Pujade-Lauraine, E; Scotto, N | 1 |
| Alexandre, J; Åvall-Lundqvist, E; Canzler, U; Colombo, N; Cormio, G; du Bois, A; Fiane, B; Hanker, LC; Harter, P; Heitz, F; Herrstedt, J; Leminen, A; Merger, M; Ottevanger, PB; Pautier, P; Poveda, A; Reinthaller, A; Reuss, A; Sehouli, J; Vergote, I | 1 |
| Calzas, J; Carrión, L; Manzanedo, I; Martínez-Torres, B; Pereira, F; Pérez-Viejo, E; Serrano, Á | 1 |
| du Bois, A; Harter, P; Hedderich, J; Heilmann, T; Hempel, AM; Hilpert, F; Pfisterer, J; Pujade-Lauraine, E; Saß, S | 1 |
| Armstrong, DK; Copeland, LJ; Java, J; Landrum, LM; Lanneau, GS; Mathews, CA; Walker, JL | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Chen, Q; Fan, L; Jiang, J; Qi, X; Wang, S; Yang, X; Zhang, Y | 1 |
| Abi-Raad, R; Brachtel, EF; Corben, AD; Koerner, FC; Macklin, EA; Popa, I; Taghian, AG; Teo, CH | 1 |
| Fujiwara, K; Iwasaki, S; Muraji, M; Nishimura, R; Sudo, T; Ueno, S; Wakahashi, S; Yamaguchi, S | 1 |
| Biermann, K; Shapiro, J; ten Kate, FJ; van Hagen, P; van Lanschot, JJ; Wijnhoven, BP | 1 |
| Bookman, MA | 1 |
| Beukema, J; Hospers, G; Karrenbeld, A; Kluin, P; Langendijk, J; Muijs, C; Mul, V; Plukker, J; Smit, J; van Dam, G | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; O'Malley, DM; Salani, R | 1 |
| Abubaker, K; Ahmed, N; Burns, CJ; Findlay, JK; Luwor, RB; McNally, O; Quinn, MA; Thompson, EW; Zhu, H | 1 |
| Ercoli, A; Fagotti, A; Margariti, PA; Pedone Anchora, L; Petrillo, M; Salutari, V; Scambia, G; Tortorella, L; Zannoni, GF | 1 |
| Cascales-Campos, PA; Feliciangeli, E; Gil, E; Gil, J; González-Gil, A; López, V; Nieto, A; Parrilla, JJ; Parrilla, P; Ruiz-Pardo, J | 1 |
| Fukuchi, M; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, O | 1 |
| Albarracin, C; Downs-Kelly, E; Gould, R; Hatzis, C; Morkowski, J; Peintinger, F; Sinn, B; Symmans, WF | 1 |
| Duk, MJ; Pasker-de Jong, PC; Schreuder, HW; van Vliet, MM | 1 |
| Bian, C; Li, L; Yao, K; Yi, T; Zhao, X | 1 |
| Burger, RA; Cohn, DE; Duska, LR; Java, JJ | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Kim, JH; Lee, EJ; Lee, TJ; Nguyen, TM; Park, J; Park, MS; Shin, IW | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Blassl, C; Chebouti, I; Fehm, T; Kasimir-Bauer, S; Kimmig, R; Neubauer, H; Wimberger, P | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T | 1 |
| Hou, J; Hu, Y; Li, F; Lu, Q; Wang, H; Wang, L; Xiang, W; Yu, X; Zeng, W; Zhang, Z | 1 |
| Chi, DS; Gardner, GJ; Iasonos, A; Kelly, A; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Sonoda, Y; Zhou, Q; Zivanovic, O | 1 |
| Alvarez-Secord, A; Copeland, LJ; Creasman, WT; Hanjani, P; Java, JJ; Kesterson, JP; Morgan, MA; Morris, RT; Rose, PG; Stehman, FB; Warshal, DP | 1 |
| Alvarez Secord, A; Armstrong, DK; Cohn, DE; Copeland, LJ; Garcia-Soto, AE; Java, JJ; Lele, SB; Nieves Neira, W; Pearson, JM; Tewari, KS; Walker, JL | 1 |
| Bousamra, A; Brewster, AM; Buchholz, TA; Buzdar, AU; Gould, R; Hatzis, C; Hortobagyi, GN; Hunt, K; Liu, M; Moulder, S; Pusztai, L; Ramineni, M; Sinn, B; Symmans, WF; Valero, V; Walls, A; Wei, C; Yang, W; Yu, X; Zhang, Y | 1 |
| Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF | 1 |
| Beesley, J; Brown, R; Byth, K; Chenevix-Trench, G; DeFazio, A; Fereday, S; Harnett, PR; Johnatty, SE; Marsh, S; McLeod, H; Paul, J; Spurdle, AB; Webb, PM | 1 |
| Ding, H; Liu, FY; Tang, L; Xiong, Y; Zheng, M | 1 |
| du Bois, A; Harter, P; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A | 1 |
| Ballardini, M; Conte, PF; Fertonani, C; Gadducci, A; Katsaros, D; Maggi, L; Pasquini, E; Pecorelli, S; Scambia, G; Zola, P | 1 |
| Duvillard, P; Ferron, JG; Gouy, S; Lhommé, C; Morice, P; Pautier, P; Rey, A; Uzan, C | 1 |
| Dietz, A; Mekonnen, B; Mozet, C; Stumpp, P | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Chatelut, E; Dalenc, F; Ferron, G; Gladieff, L | 1 |
| Hou, JL; Li, XG; Liu, LY; Wu, LY; Yao, HW; Yuan, GW | 1 |
| Burges, A; du Bois, A; Harter, P; Kimmig, R; Lehmann, N; Pfisterer, J; Schmalfeldt, B; Wehling, M; Wimberger, P | 1 |
| Gu, YJ; Mao, J; Peng, WJ; Tan, HN; Tang, F; Wang, XH; Xin, C | 2 |
| Ajani, JA; Hofstetter, WL; Komaki, RU; Konski, AA; Swisher, SG; Willett, CG; Winter, KA; Wu, TT | 1 |
| Cui, H; Kong, L; Li, X; Wang, J; Wang, S; Wei, L; Xu, Q; Zhao, Y | 1 |
| Armstrong, DK; Chernofsky, MR; Farley, JH; Hamilton, CA; Krivak, TC; Markman, M; Maxwell, GL; Miller, A; Miller, C; Ozols, RF; Rose, GS; Stany, MP | 1 |
| Hwang, JH; Jong, YH; Kang, S; Lim, MC; Park, SY; Seo, SS; Yoo, CW | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Bahri, S; Butler, JA; Carpenter, PM; Chen, JH; Feig, SA; Hsiang, DJ; Kuzucan, A; Lane, KT; Lin, M; Mehta, RS; Nalcioglu, O; Su, MY; Yu, HJ | 1 |
| Chang, TC; Chou, HH; Hong, JH; Huang, YT; Lai, CH; Lee, SP; Tsai, CS; Wang, CC | 1 |
| Brennan, D; Fennelly, D; Flannelly, G; Foley, M; Lenehan, P; Shireen, R | 1 |
| Bristow, RE; Chang, SJ; Ryu, HS | 1 |
| Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R | 1 |
| Chang, HK; Chen, SC; Cheung, YC; Hsueh, S; Lin, YC; See, LC; Su, MY; Tsai, CS | 1 |
| Mayer, A; Pete, I; Pulay, T; Szánthó, A; Thurzó, L | 1 |
| Inoue, H; Kikuchi, Y; Kita, T; Kudoh, K; Oogi, S; Yamamoto, K | 1 |
| Buzdar, AU; Fiterman, DJ; Frye, D; Gal-Gombos, E; Green, M; Hortobagyi, GN; Kuerer, H; Poniecka, A; Pusztai, L; Rajan, R; Rouzier, R; Smith, TL; Symmans, WF; Whitman, G; Yang, Y | 1 |
| Beyer, J; Bokemeyer, C; Braun, T; Hartmann, JT; Hartmann, M; Pottek, T; Rachud, B; Rick, O; Schirren, J; Siegert, W; Weinknecht, S; Weissbach, L | 1 |
| Ames, FC; Babiera, GV; Buzdar, AU; Chagpar, AB; Dempsey, P; Feig, BW; Hunt, KK; Kuerer, HM; Meric-Bernstam, F; Middleton, LP; Mirza, AN; Ross, MI; Sahin, AA; Singletary, SE | 1 |
| Berry, D; Delaloge, S; Garbay, JR; Hortobagyi, GN; Hunt, KK; Kuerer, HM; Pusztai, L; Rouzier, R | 1 |
| Burges, A; Du Bois, A; Kimmig, R; Lehmann, N; Meier, W; Wimberger, P | 1 |
| Chen, FJ; Feng, YL; Gao, KF; Liu, FY | 1 |
| Droz, JP; Fléchon, A | 1 |
| Maxwell, GL; McGuire, WP; Muggia, F; Rose, GS; Rose, PG; Rubin, SC; Sundborg, MJ; Tian, C; Winter, WE | 1 |
| Carpenter, PM; Chen, JH; Mehta, RS; Nalcioglu, O; Su, MY | 1 |
| Eisele, DW; Glastonbury, CM; Lin, D; Rafaelian, O; Wang, SJ | 1 |
| Altundag, K; Buzdar, AU; Esteva, FJ; Hortobagyi, GN; Lin, F; Mejia, JA; Pusztai, L; Symmans, WF; Valero, V; Wang, J; Yan, K | 1 |
| Averette, HE; Method, MW; Penalver, MA; Rodriguez, M; Serafini, AN; Sevin, BU | 1 |
| Fennelly, D; Gogas, H | 1 |
| Erlanger, B; Fetell, MR; Fisher, JD; Grossman, SA; Piantadosi, S; Rowinsky, E; Stockel, J | 1 |
| Bauknecht, T; Costa, S; du Bois, A; Jackisch, C; Lück, HJ; Meier, W; Möbus, V; Nitz, U; Olbricht, S; Richter, B; Schröder, W; Warm, M | 1 |
| Benito, D; Casado, A; Cervantes, A; del Campo, JM; Escobedo, A; Massuti, B; Mendiola, C; Moyano, A; Ojeda, B; Poveda, A | 1 |
| Aravantinos, G; Athanassiadis, A; Bafaloukos, D; Bamia, C; Fountzilas, G; Karphathios, S; Kosmidis, P; Papakostas, P; Pavlidis, N; Skarlos, DV; Stathopoulos, GP | 1 |
| Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Kim, HJ; Lowe, V; McDonough, EM; Minster, J; Rodriguez, J; Varvares, MA | 1 |
| Brady, MF; Hanjani, P; Markman, M; Rubin, SC; Spirtos, NM | 1 |
| Becker, A; Dunst, J; Heynemann, H; Weigel, C | 1 |
| Gnant, M; Jakesz, R; Locker, GJ; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Ames, FC; Buzdar, AU; Feig, BW; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Vlastos, G | 1 |
| Agarwal, S; Awasthy, BS; Julka, PK; Mahapatra, AK; Rath, GK; Singh, R; Varna, T | 1 |
| Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G | 1 |
| Bristow, RE; Grumbine, FC; Montz, FJ; Rosenshein, NB; Zerbe, MJ | 1 |
| Aghajanian, C; Barakat, R; Makhija, S; Sabbatini, P; Spriggs, DR; Venkatraman, E | 1 |
| Bolis, G; Mangili, G; Parazzini, F; Scarfone, G; Tateo, S; Villa, A | 1 |
| Alberts, DS; Bundy, BN; Carson, LF; Clark-Pearson, DL; Fowler, JM; Markman, M; Sickel, J; Wadler, S | 1 |
| Arditti, J; Catalin, J; Chastagner, P; Doz, F; Frappaz, D; Gentet, JC; Iliadis, A; Moretti, S; Pein, F; Tellingen, OV; Vassal, G | 1 |
| Atkins, MB; DeWolf, WC; Gollob, JA; Upton, MP | 1 |
| Adachi, S; Fujita, H; Hara, Y; Hiraoka, K; Honjo, H; Hosokawa, K; Itani, Y; Itoh, K; Itoh, R; Kimura, T; Koishi, K; Koshiba, H; Nakata, Y; Toyoda, S; Tsuchiya, H; Yamada, T; Yamagami, K | 1 |
6 review(s) available for paclitaxel and Minimal Disease, Residual
| Article | Year |
|---|---|
Do we have a new standard in suboptimal debulked disease?
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel | 2013 |
[Therapeutic options in sinunasal adenoid cystic carcinomas--a case report and review].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenoid Cystic; Chemotherapy, Adjuvant; Combined Modality Therapy; Endoscopy; Female; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Orbit; Paclitaxel; Paranasal Sinus Neoplasms; Pterygopalatine Fossa; Radiotherapy, Adjuvant; Skull Neoplasms; Sphenoid Bone; Sphenoid Sinus; Surgery, Computer-Assisted; Tomography, X-Ray Computed | 2009 |
[Pharmacological bases of intraperitoneal chemotherapy].
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carboplatin; Cisplatin; Female; Humans; Infusions, Parenteral; Mice; Models, Animal; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneum | 2009 |
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Outcome | 2010 |
[Testis germ cell tumours: which chemotherapy, for which patients?].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Ifosfamide; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Positron-Emission Tomography; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Seminoma; Testicular Neoplasms; Testis; Vinblastine | 2007 |
Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Dexamethasone; Etoposide; Female; Humans; Middle Aged; Neoplasm, Residual; Osteonecrosis; Ovarian Neoplasms; Paclitaxel | 1996 |
36 trial(s) available for paclitaxel and Minimal Disease, Residual
| Article | Year |
|---|---|
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Intention to Treat Analysis; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Postoperative Complications; Prospective Studies; Quality of Life; Survival Rate; Thoracoscopy | 2021 |
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Young Adult | 2018 |
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel | 2019 |
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Young Adult | 2019 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Treatment Outcome | 2013 |
Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis | 2014 |
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm, Residual; Paclitaxel; Prognosis; Reproducibility of Results; Survival Rate; Tumor Burden | 2015 |
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors | 2015 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dissection; Drug Combinations; Esophagogastric Junction; Feasibility Studies; Female; Gastrectomy; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2016 |
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Reoperation; Survival Rate | 2016 |
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzin
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Survival Analysis; Treatment Outcome | 2009 |
Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 mu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Second-Look Surgery | 2009 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2012 |
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Treatment Outcome | 2004 |
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVA
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Female; Humans; Logistic Models; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Survival Rate | 2007 |
[Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Follow-Up Studies; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2007 |
The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Image Processing, Computer-Assisted; Indium Radioisotopes; Laparotomy; Mice; Middle Aged; Neoplasm, Residual; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Pentetic Acid; Predictive Value of Tests; Prospective Studies; Radioimmunodetection; Remission Induction; Sensitivity and Specificity; Single-Blind Method; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 1996 |
Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Interactions; Female; Glioblastoma; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm, Residual; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome | 1997 |
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Arthralgia; Carboplatin; Dose-Response Relationship, Drug; Female; Germany; Humans; Infusions, Intravenous; Middle Aged; Neoplasm, Residual; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pain; Patient Selection; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Single-Blind Method; Survival Rate; Thrombocytopenia; Vomiting | 1997 |
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Laparotomy; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Reoperation; Spain; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cause of Death; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Greece; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 1997 |
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate | 1998 |
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme.
Topics: Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm, Residual; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Survival Rate | 2000 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids | 2000 |
Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epithelium; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Reoperation; Retrospective Studies; Survival Analysis | 2000 |
Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm, Residual; Paclitaxel; Topotecan | 2001 |
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecol
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel | 2001 |
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Drug Hypersensitivity; Ethanol; Female; Humans; Infant; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm, Residual; Neurotoxicity Syndromes; Paclitaxel; Polyethylene Glycols; Solvents | 2001 |
[Phase II study of combination therapy with paclitaxel and carboplatin against postoperative small residual disease in patients with stage I c-IV ovarian cancer--KCOG 989 trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel | 2002 |
60 other study(ies) available for paclitaxel and Minimal Disease, Residual
| Article | Year |
|---|---|
A neutrophil-mediated carrier regulates tumor stemness by inhibiting autophagy to prevent postoperative triple-negative breast cancer recurrence and metastasis.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydroxychloroquine; Inflammation; Liposomes; Neoplasm, Residual; Neutrophils; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Fertility sparing therapy in women with lymph node negative cervical cancer >2cm - oncologic and fertility outcomes of neoadjuvant chemotherapy followed by radical vaginal trachelectomy.
Topics: Adult; Cisplatin; Female; Fertility Preservation; Humans; Ifosfamide; Lymph Nodes; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Pregnancy; Retrospective Studies; Trachelectomy; Uterine Cervical Neoplasms | 2023 |
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Rate | 2020 |
Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2021 |
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Hyperthermic Intraperitoneal Chemotherapy; Laparoscopy; Length of Stay; Male; Mesothelioma; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm, Residual; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Registries; Severity of Illness Index; Survival Rate; Tumor Burden | 2021 |
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.
Topics: Adipocytes; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cytoreduction Surgical Procedures; Epithelial-Mesenchymal Transition; Fatty Acids; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplastic Stem Cells; Ovarian Neoplasms; Oxidation-Reduction; Paclitaxel; Transcriptome | 2021 |
Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Survival Rate | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Rapid
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Drug Therapy, Combination; Epirubicin; Gliosarcoma; Humans; Hydrogels; Infusion Pumps, Implantable; Magnetic Resonance Imaging; Mice; Neoplasm, Residual; Paclitaxel; Secondary Prevention; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured | 2017 |
Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery : Long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Prognosis; Survival Rate | 2018 |
The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Doxorubicin; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies | 2019 |
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Drug Administration Schedule; Epirubicin; Female; Humans; Medication Adherence; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Topotecan; Tumor Burden; Young Adult | 2019 |
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Lymphatic Metastasis; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2013 |
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Mucous Membrane; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Paclitaxel; Treatment Outcome | 2013 |
Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Prospective Studies; Radiography; Radiotherapy Planning, Computer-Assisted; Regression Analysis; Tumor Burden | 2014 |
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Janus Kinase 2; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cohort Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Burden | 2014 |
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2015 |
Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cyclophosphamide; Cytoreduction Surgical Procedures; Delivery of Health Care; Disease-Free Survival; Female; Follow-Up Studies; Health Status; Hospitals, Teaching; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2015 |
Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; China; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2016 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Topics: Adenoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Tumor Stem Cell Assay | 2016 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Prognosis | 2016 |
Value of intravoxel incoherent motion and dynamic contrast-enhanced MRI for predicting the early and short-term responses to chemoradiotherapy in nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chemoradiotherapy; Contrast Media; Diffusion Magnetic Resonance Imaging; Dose Fractionation, Radiation; Female; Gadolinium DTPA; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm, Residual; Organoplatinum Compounds; Paclitaxel; Perfusion; Predictive Value of Tests; ROC Curve; Time Factors; Treatment Outcome | 2016 |
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2016 |
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Time Factors | 2016 |
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Phenotype; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Rate; Time Factors; Trastuzumab; Tumor Burden | 2017 |
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2008 |
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2008 |
[Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Tumor Burden; Young Adult | 2008 |
Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cell Survival; Drug Therapy; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Treatment Outcome | 2009 |
[Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies; Survival Rate | 2009 |
[Value of diffusion weighted imaging (DWI) in evaluating early response to neoadjuvant chemotherapy in locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Diffusion Magnetic Resonance Imaging; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Prospective Studies; Young Adult | 2010 |
[Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Contrast Media; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel | 2010 |
The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies | 2011 |
Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Patient Selection; Prognosis; Prospective Studies; Retrospective Studies | 2011 |
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Contrast Media; Cyclophosphamide; Doxorubicin; Female; Gadolinium DTPA; Humans; Image Interpretation, Computer-Assisted; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Trastuzumab; Treatment Outcome | 2011 |
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Salvage Therapy; Survival Rate; Treatment Failure; Uterine Cervical Neoplasms; Young Adult | 2012 |
Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Female; Humans; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel | 2012 |
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pelvis; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies | 2012 |
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Prospective Studies; Remission Induction; Treatment Outcome | 2003 |
[Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Administration Schedule; Erythropoietin; Female; Humans; Hungary; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Endometrioid; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Reoperation | 2004 |
Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Necrosis; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retroperitoneal Neoplasms; Retrospective Studies; Testicular Neoplasms | 2004 |
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Physical Examination; Predictive Value of Tests; Retrospective Studies; Statistics, Nonparametric; Ultrasonography, Mammary | 2006 |
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Nomograms; Paclitaxel; Probability; Prognosis; Software; Treatment Outcome | 2006 |
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Medical Records; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Postoperative Complications; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2008 |
Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Pregnancy; Pregnancy Complications, Neoplastic; Receptor, ErbB-2; Remission Induction | 2007 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast Neoplasms; CD40 Antigens; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mastectomy; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; RNA, Messenger; Signal Transduction; Transcription, Genetic; Trastuzumab; Treatment Outcome; Up-Regulation | 2007 |
Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Immunohistochemistry; Middle Aged; Mutation; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Tumor Suppressor Protein p53 | 1997 |
Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Paclitaxel; Radiation-Sensitizing Agents; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Feasibility Studies; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction | 2000 |
Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Surgical Procedures, Operative; Survival Analysis; Time Factors | 2000 |
Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Kidney Tubules, Distal; Neoplasm, Residual; Nephrectomy; Paclitaxel; Remission Induction | 2001 |